The Role of Everolimus in Renal Cell Carcinoma
<p>Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Codon Publications
2015-12-01
|
| Series: | Journal of Kidney Cancer and VHL |
| Subjects: | |
| Online Access: | http://jkcvhl.com/index.php/jkcvhl/article/view/43 |